UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/691,117	10/21/2003	David J. Vachon	1695.003	5330
	7590 06/03/200 AASCH & GEBHARD	EXAMINER		
P.O. BOX 581336			BROOKS, KRISTIE LATRICE	
MINNEAPOLIS, MN 55458-1336			ART UNIT	PAPER NUMBER
			1616	
			MAIL DATE	DELIVERY MODE
			06/03/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/691,117	VACHON ET AL.
Office Action Summary	Examiner	Art Unit
	KRISTIE L. BROOKS	1616
The MAILING DATE of this communication appeariod for Reply	pears on the cover sheet with the o	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tinwill apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
 Responsive to communication(s) filed on <u>26 F</u> This action is FINAL. 2b) This Since this application is in condition for alloward closed in accordance with the practice under E 	s action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 15-17,30-32 and 34-48 is/are pending 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 15-17,30-32, and 34-48 is/are rejected 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or and/or claim(s) are subject to restriction.	wn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	cepted or b) objected to by the liderawing(s) be held in abeyance. Section is required if the drawing(s) is objected.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicati ority documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 2/26/09.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate

Art Unit: 1616

DETAILED ACTION

Continued Examination under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 26, 2009 has been entered.

Status of Application

- 2. Claims 15-17, 30-32 and 34-48 are pending. Claims 40-48 are new.
- 3. Receipt and consideration of Applicants remarks/arguments submitted on February 26, 2009 is acknowledged.
- 4. Rejections not reiterated from the previous Office Action are hereby withdrawn.

 The following rejections are either reiterated or newly applied. They constitute the complete set of rejections presently being applied to the instant application.

Claim Rejections - 35 USC § 103

- 5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Art Unit: 1616

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 6. Claims 15-17, 29-30, 34-46 and 48 are rejected under 35 U.S.C. 103(a) as being unpatentable over Klier et al. (US 2004/0081829).

Applicant claims a method for controlling biological organisms on a porous surface said method comprising forming a water-insoluble coating comprising at least one salt of a polysulfonated block polymer hydrogel on the porous surface said porous surface is an article selected from the group comprising a garment, a gas filter, a laboratory work surface, a laboratory wipe, and a wound dressing or said porous surface comprises paper or fabric.

Determination of the scope and content of the prior art (MPEP 2141.01)

Klier et al. teach an absorbent polymer composition comprising A) sulfonated substantially random interpolymers and B) one or more polymers other than said sulfonated substantially random interpolymer (see page 1 paragraph 4 and page 2 paragraphs 19-24). The sulfonated substantially random interpolymers are derived from ethylene and/or one or more alpha olefins (i.e. propylene, butene-1, hexen-1, etc.), one

Page 4

or more sulfonated vinyl or vinylidene aromatic monomers, and vinyl or vinylidene aromatic monomers (i.e. styrene) (see page 3 paragraph 46-47, and page 4 paragraphs 48-49). The one or more polymers other than said sulfonated substantially random interpolymer include homogenous α-olefin homopolymer or interpolymer, block copolymers, such as SIS, SEBS, thermoplastic polyurethanes, etc. (see page 6 paragraphs 72-73). The sulfonated substantially random interpolymers can be in either the sulfonic acid from, or as a neutralized or partially neutralized salt with neutralizing agents or bases, such as, ammonium, ammonium hydroxide, sodium hydroxide, etc. (see page 1 paragraph 4 and page 6 paragraph 68). The absorbent polymer compositions can be used on articles for personal hygiene, such as diapers, or absorbent wipes, fabrics, garments, films, bandages, medical applications for delivering pharmaceuticals, etc. (see page 2 paragraph 25, page 3 paragraph 34, and page 12 paragraphs 139-141). The article may be crosslinked or uncrosslinked dependent on the article made (see column

Ascertainment of the difference between the prior art and the claims (MPEP 2141.02)

Klier et al. do not exemplify forming a coating with the instant salt of a polysulfonated hydrogel on the instantly claimed porous surfaces. Further, Klier et al. do not exemplify the instant method of controlling biological organisms on a porous surface with the instant salt of a polysulfonated hydrogel.

Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143)

One of ordinary skill in the art would have been motivated to form a coating with the instant salt of a polysulfonated hydrogel on the instantly claimed porous surfaces because Klier et al. suggest the instant compounds for the preparation of and application to fabrics, garments, bandages, films, wipes, diapers, etc. or any article used for absorbent purposes.

Thus, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to form a coating with the instant salt of a polysulfonated hydrogel on the instantly claimed porous surfaces since they are all useful absorbent articles that the instant compounds are useful for.

With regard to the preamble in claim 1 and 39, i.e. a method for controlling biological organisms on a porous surface, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to control biological organisms with the instant polysulfonated hydrogel because, absence evidence to the contrary, since the method steps of the prior art and the instant invention are the same, i.e. forming a coating on a porous surface with the same salt of a polysulfonated hydrogel, the claimed method would implicitly occur upon application to said porous surface.

Therefore, the claimed method would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made because the prior art is fairly suggestive of the claimed method.

7. Claims 31-32 and 47 are rejected under 35 U.S.C. 103(a) as being unpatentable over Klier et al. (US 2004/0081829) in view of Wood et al. (US 5,260,066).

Applicant claims a method for controlling biological organisms on a porous surface said method comprising forming a water-insoluble coating comprising at least one salt of a polysulfonated hydrogel on the porous surface said porous surface is an article selected from the group comprising a garment, a gas filter, a laboratory work surface, a laboratory wipe, and a wound dressing or said porous surface comprises paper or fabric.

Determination of the scope and content of the prior art (MPEP 2141.01)

Klier et al. teach an absorbent polymer composition comprising A) sulfonated substantially random interpolymers and B) one or more polymers other than said sulfonated substantially random interpolymer (see page 1 paragraph 4 and page 2 paragraphs 19-24). The sulfonated substantially random interpolymers are derived from ethylene and/or one or more alpha olefins (i.e. propylene, butene-1, hexen-1, etc.), one or more sulfonated vinyl or vinylidene aromatic monomers, and vinyl or vinylidene aromatic monomers (i.e. styrene) (see page 3 paragraph 46-47, and page 4 paragraphs

48-49). The one or more polymers other than said sulfonated substantially random interpolymer include homogenous α -olefin homopolymer or interpolymer, block copolymers, such as SIS, SEBS, thermoplastic polyurethanes, etc. (see page 6 paragraphs 72-73). The sulfonated substantially random interpolymers can be in either the sulfonic acid from, or as a neutralized or partially neutralized salt with neutralizing agents or bases, such as, ammonium, ammonium hydroxide, sodium hydroxide, etc. (see page 1 paragraph 4 and page 6 paragraph 68). The absorbent polymer compositions can be used in the preparation and for application to articles for personal hygiene, such as diapers, or absorbent wipes, fabrics, garments, films, bandages, medical applications for delivering pharmaceuticals, etc. (see page 2 paragraph 25, page 3 paragraph 34, and page 12 paragraphs 139-141).

Ascertainment of the difference between the prior art and the claims (MPEP 2141.02)

Klier et al. do not exemplify forming a coating with a tetracycline, such as, doxycycline. This deficiency is cured by the teachings of Wood et al.

Wood et al. teach a controlled release bandage comprising therapeutic agents in polymeric cryogels (see the abstract). The bandage provides a controlled release and a sterile infection resisting bandage for protecting sites against damage (see column 3

Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143)

One of ordinary skill in the art would have been motivated to incorporate a tetracycline, such as, doxycycline, in the instant polysulfonated hydrogel coating because Klier et al. suggest the instant compounds are useful in bandages and medical applications for delivering pharmaceuticals.

Thus, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to incorporate a tetracycline, such as, doxycycline, in the instant coating because it is obvious additional component to be added to polymeric compositions in medical bandages for delivering pharmaceuticals as suggested by Wood et al. Furthermore, it will enhance the effectiveness of the coating by providing additional protection against the growth of biological organisms.

Therefore, the claimed method would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made because the prior art is fairly suggestive of the claimed method.

Response to Arguments

Applicant's arguments filed February 26, 2009 have been fully considered but they are not persuasive.

Application/Control Number: 10/691,117

Art Unit: 1616

Applicant argues that the polysulfonated block hydrogels are different from the presently claimed sulfonated substantially random interpolymers disclosed by Klier et al. Applicant, further adds evidence by pointing to the instant specification that discloses the intended benefits of the instantly claimed polysulfonated block polymers hydrogels.

Page 9

These arguments are not convincing. Applicant claims polysulfonated block polymer hydrogels. The amount of polymers and different combination of polymers that are encompassed by the instant claim is very broad. Klier et al. teach the use of sulfonated interpolymers that are absorbent. The term "interpolymers" includes using at least two different monomers that are polymerized to make the interpolymer. Thus, block polymers are encompassed by the term "interpolymers". Furthermore, it is known in the art that interpolymers are formed by the use of block polymers and can result in the production of block terminated block polymers (as evidenced by Wollum et al. US 6,162,874). Thus, Applicant has not provided any evidence to suggest that the sulfonated interpolymers taught by Klier et al. cannot be polysulfonated block polymers. Moreover, in response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., added benefits) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Next, Applicant argues that the preparation of the polysulfonated block copolymer requires the use of cross-linking agents.

Art Unit: 1616

This argument is not convincing. Klier et al. describes the use of absorbent and/or superabsorbent applications. Although Klier et al. teach a superabsorbent polymer that is prepared by the use of crosslinking agents for superabsorbent applications, this teaching is not in reference to the preparation of the sulfonated interpolymer blend that is used with the absorbent applications (see page 3 paragraph 33). Thus the cross-linking agents are not required for use in the preparation of the sulfonated interpolymer blend.

Therefore Applicant's arguments of nonobviousness is not persuasive and the rejection is maintained.

Conclusion

8. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIE L. BROOKS whose telephone number is (571)272-9072. The examiner can normally be reached on M-F 8:30am-6:00pm Est..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann R. Richter can be reached on (571) 272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

KΒ

/Johann R. Richter/
Supervisory Patent Examiner, Art Unit 1616